Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2016', provides an overview of the Thrombotic Thrombocytopenic Purpura pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura - The report reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Thrombotic Thrombocytopenic Purpura therapeutics and enlists all their major and minor projects - The report assesses Thrombotic Thrombocytopenic Purpura therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Thrombotic Thrombocytopenic Purpura - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Thrombotic Thrombocytopenic Purpura Overview 7 Therapeutics Development 8 Pipeline Products for Thrombotic Thrombocytopenic Purpura - Overview 8 Pipeline Products for Thrombotic Thrombocytopenic Purpura - Comparative Analysis 9 Thrombotic Thrombocytopenic Purpura - Therapeutics under Development by Companies 10 Thrombotic Thrombocytopenic Purpura - Therapeutics under Investigation by Universities/Institutes 11 Thrombotic Thrombocytopenic Purpura - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Thrombotic Thrombocytopenic Purpura - Products under Development by Companies 15 Thrombotic Thrombocytopenic Purpura - Products under Investigation by Universities/Institutes 16 Thrombotic Thrombocytopenic Purpura - Companies Involved in Therapeutics Development 17 Ablynx NV 17 Biogen, Inc. 18 Glenmark Pharmaceuticals Ltd. 19 Kaketsuken K.K. 20 Lee's Pharmaceutical Holdings Limited 21 Octapharma AG 22 Omeros Corporation 23 Thrombotic Thrombocytopenic Purpura - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 ARC-15105 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 BAX-930 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 caplacizumab - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 GBR-600 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 OMS-721 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 plasma (human) - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 rituximab - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 ZK-001 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Thrombotic Thrombocytopenic Purpura - Recent Pipeline Updates 49 Thrombotic Thrombocytopenic Purpura - Dormant Projects 57 Thrombotic Thrombocytopenic Purpura - Product Development Milestones 58 Featured News & Press Releases 58 Feb 11, 2016: New England Journal Of Medicine Publishes Ablynx Phase II Titan Study Of Caplacizumab in Patients With Acquired TTP 58 Sep 29, 2015: Ablynx Initiates A Multinational Phase III Study With Caplacizumab In Patients With Acquired TTP 59 Jun 17, 2015: Ablynx Announces Presentations On Its Potential First-In-Class Treatment For Acquired TTP, Caplacizumab, At The 2015 Annual Meeting Of The ISTH 60 Feb 19, 2015: Omeros Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use 60 Dec 08, 2014: Additional Clinical Data From The Phase II Study With Ablynx'S Anti-Vwf Nanobody, Caplacizumab, Presented At The American Society Of Hematology Annual Meeting 61 Nov 26, 2014: Ablynx Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti Vwf nanobody, Caplacizumab 63 Jun 17, 2014: Ablynx's Anti-vWF Nanobody, Caplacizumab, achieves Clinical Proof-of-concept in Phase II Titan Study 64 Apr 03, 2014: Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies 65 Jul 28, 2011: Initial Observations Of ABLYNX'S PHASE II TTP Program Presented At ISTH Congress 66 Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For ALX-0081 66 Appendix 68 Methodology 68 Coverage 68 Secondary Research 68 Primary Research 68 Expert Panel Validation 68 Contact Us 68 Disclaimer 69
List of Tables
Number of Products under Development for Thrombotic Thrombocytopenic Purpura, H1 2016 8 Number of Products under Development for Thrombotic Thrombocytopenic Purpura - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Thrombotic Thrombocytopenic Purpura - Pipeline by Ablynx NV, H1 2016 17 Thrombotic Thrombocytopenic Purpura - Pipeline by Biogen, Inc., H1 2016 18 Thrombotic Thrombocytopenic Purpura - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 19 Thrombotic Thrombocytopenic Purpura - Pipeline by Kaketsuken K.K., H1 2016 20 Thrombotic Thrombocytopenic Purpura - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 21 Thrombotic Thrombocytopenic Purpura - Pipeline by Octapharma AG, H1 2016 22 Thrombotic Thrombocytopenic Purpura - Pipeline by Omeros Corporation, H1 2016 23 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Stage and Target, H1 2016 26 Number of Products by Stage and Mechanism of Action, H1 2016 28 Number of Products by Stage and Route of Administration, H1 2016 30 Number of Products by Stage and Molecule Type, H1 2016 32 Thrombotic Thrombocytopenic Purpura Therapeutics - Recent Pipeline Updates, H1 2016 49 Thrombotic Thrombocytopenic Purpura - Dormant Projects, H1 2016 57
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.